Sector News

GSK expanding U.S. site to produce more Benlysta

May 1, 2017
Life sciences

With demand for GlaxoSmithKline’s lupus-fighter Benlysta growing in the U.S. and approval of a new formulation expected later this year, the U.K., drugmaker says it is time to bring on more capacity at a U.S. manufacturing facility.

GSK today said it will invest $139 million at its biopharma site in Rockville, Maryland, allowing it to expand bulk drug capacity by about 50% for the intravenous drug, as well as a new subcutaneous formulation for which GSK hopes to get approval later this year. Work has started on the project and the added production is expected to be online in 2019.

The announcement came on the first day of Lupus Awareness Month.

Approved in 2014, Benlysta continues to be a growing product for GSK, increasing at least 18% per year in the U.S. on a constant exchange rate basis, the company said. Last year, GSK reported $377 million (£277 million) in sales for the drug in the U.S., and revenues for the med grew even more this quarter, up 22% to $117.7 million (£91 million) worldwide.

This is the second big expansion for the Rockville site, located outside of Washington, D.C., where about 400 people work. In December, GSK opened a $50 million vaccine R&D center at the facility where scientists will research potential deadly outbreaks.

It is also the second major manufacturing expansion announced by the drugmaker in the last couple of months. In March, it said it would build a $175 million biopharma facility at its site in Marburg, Germany, so it can expand production of the meningococcal B shot Bexsero. GSK expects to start validation runs at that facility in the third quarter of 2020.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach